- Home
- VTYX vs EVMN Comparison
VTYX vs EVMN Comparison
Compare VTYX & EVMN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | VTYX | EVMN |
|---|---|---|
| Founded | 2018 | 2020 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 990.9M | 892.4M |
| IPO Year | 2021 | N/A |
Fundamental Metrics
Financial Performance| Metric | VTYX | EVMN |
|---|---|---|
| Price | $13.99 | $21.69 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 7 | 8 |
| Target Price | $13.50 | ★ $44.17 |
| AVG Volume (30 Days) | ★ 3.8M | 386.4K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 40.30 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.90 | $13.89 |
| 52 Week High | $15.34 | $33.20 |
Technical Indicators
Market Signals| Indicator | VTYX | EVMN |
|---|---|---|
| Relative Strength Index (RSI) | 72.58 | 41.90 |
| Support Level | $13.89 | $15.25 |
| Resistance Level | $14.07 | $23.08 |
| Average True Range (ATR) | 0.03 | 2.25 |
| MACD | -0.11 | -0.80 |
| Stochastic Oscillator | 88.89 | 8.28 |
Price Performance
Historical ComparisonAbout VTYX Ventyx Biosciences Inc.
Ventyx Biosciences Inc is a clinical-stage biopharmaceutical company focused on advancing new therapies for millions of patients living with inflammatory diseases and autoimmune, and neurodegenerative disorders. The company is developing a pipeline of novel small-molecule product candidates to address a range of inflammatory diseases. Its product candidate VTX958 is an oral, selective clinical-stage tyrosine kinase type 2 (TYK2) inhibitor designed to inhibit TYK2 without detectable inhibition of other Janus kinase (JAK) isoforms, which avoids toxicities associated with broader JAK inhibition and, thus, other JAK inhibitors.
About EVMN Evommune Inc.
Evommune Inc is a clinical-stage biotechnology company focused on creating new therapies aimed at key factors driving chronic inflammatory diseases. The initial clinical programs of the company target chronic spontaneous urticaria (CSU), atopic dermatitis (AD), and ulcerative colitis (UC). The pipeline products of the company include EVO756 and EVO301.